← Back to patent-cliff list
CAS 518048-03-8
2-(2-aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide
Codes: RALT-009
Application context (from source-drug indications)
HIV infectionRaltegravir PotassiumSclerosing cholangitisRaltegravir PotassiumHTLV-I infectionRaltegravir PotassiumChronic renal impairmentRaltegravir PotassiumRelapsing-remitting multiple sclerosisRaltegravir PotassiumHypertriglyceridaemiaRaltegravir Potassium
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Raltegravir Potassium | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-hydroxy-2-methylpropanenitrile→2-amino-2-methylpropanenitrile→benzyl (2-cyanopropan-2-yl)carbamate→benzyl (Z)-(1-amino-1-(hydroxyimino)-2-methylpropan-2-yl)carbamate→methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylate→methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate→(4-fluorophenyl)methanamine→benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate→2-(2-aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide→5-methyl-1,3,4-oxadiazole-2-carbonyl chloride→5-methyl-1H-tetrazole→ethyl 2-chloro-2-oxoacetate→potassium 5-methyl-1,3,4-oxadiazole-2-carboxylate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.